What Is the Survival Rate for MDS Stem Cell Transplant?

A donor stem cell transplant is the only treatment that offers a real chance of curing myelodysplastic syndrome (MDS).¹ Depending mostly on how advanced the disease is when the transplant happens, roughly 30% to 70% of people are cured and live long-term.² The risk comes both from the MDS returning and from the transplant itself.

What the Survival Numbers Look Like Over Time

In an allogeneic transplant, healthy blood-forming cells from a donor replace your own marrow. In carefully selected older patients, about 9 in 10 are alive one year after transplant.³ Across broad groups of people aged 50 and over, though, about 31% were alive four years later.⁴ When MDS was caused by earlier cancer treatment, about 38% were alive at 5 years and 24% at 10 years.⁵ Someone alive at 10 years after this harder type of MDS is often truly cured, even if the disease didn’t respond to earlier treatment.⁶

Early survival mostly reflects getting through the transplant itself. After that, relapse and late complications keep lowering the numbers for the next few years.

The figure you hear also depends on who was counted. A study of carefully chosen, fit older patients will look much better than one covering everyone transplanted, so two true figures can differ widely without either being wrong.

A few habits help when you’re handed a number. A 5-year figure counts people alive at 5 years, not people who lived 5 years at most. “Disease-free survival” counts only people alive without MDS, so it runs lower than overall survival. And because the figures come from people transplanted years ago, they lag behind current care. Ask your team which group a number comes from and whether it resembles you.

Results have improved over time. Deaths from transplant complications have fallen steadily since the late 1990s, which has raised overall survival.⁷ With sibling donors, survival rose from about 44% in the 1990s to about 51% for transplants done from 2011 on.⁸ Older published averages may therefore understate today’s odds.

How Your MDS Risk Group and Genes Change the Odds

A TP53 mutation is a change in a gene that normally stops damaged cells from growing, and your marrow report will state whether it’s present. It is the strongest single predictor of how a transplant goes. In higher-risk MDS without a TP53 change, about 69% were alive five years after transplant.⁹ With a TP53 change, median survival after transplant was only about 7 to 9 months.¹⁰ Across many studies, about 21% of people with TP53-changed MDS were alive three years after transplant, and nearly 6 in 10 relapsed.¹¹ Even so, transplant still gave them longer survival than comfort-focused treatment without a transplant.¹² High-risk MDS without transplant usually progresses faster, so the decision rests on comparing transplant odds against the odds without it, not against zero.

A TP53 change is found by genetic testing of a marrow or blood sample, so the result is usually available before a transplant decision is final. Because the odds with a TP53 change are much lower, the discussion often turns to weighing a transplant’s limited chance of lasting remission against its risks and recovery burden. Some teams consider transplant in this group within a clinical trial, or with a plan for early post-transplant treatment to lower relapse risk, so it is reasonable to ask whether such options exist for you. Also ask whether one or both copies of the gene are affected; a change in both copies generally carries worse odds.

The IPSS-M is a risk score that adds gene results to blood counts and marrow findings, and you may see it on your report. It predicted relapse and survival after transplant more accurately than the older IPSS-R score.¹³ In one large group, five-year survival ranged from about 63% in low-risk groups to about 26% in the very-high-risk group.¹⁴

A category is still a group average, and age and health add to it. If your report lists only the older IPSS-R, ask whether your gene results can be used to calculate the newer one, and how your numbers compare with someone without your gene changes.

Transplant Versus Staying on Drug Treatment

In older people with advanced MDS, about 50% who went on to transplant were alive at three years, versus 32% who stayed on azacitidine.¹⁵ None of those on ongoing azacitidine were still free of disease progression at three years, compared with 34% after transplant.¹⁶

Azacitidine can bring blood counts up and slow the disease, but the abnormal cells are generally held back rather than cleared out. Over time most people on it see the disease return or progress, so having no one free of progression at three years is expected. A transplant replaces the marrow and adds donor immune cells that can keep attacking MDS cells, which is what offers a chance at lasting remission.

The two paths feel very different day to day. Azacitidine means repeated outpatient injection or infusion cycles with milder side effects, continuing indefinitely. Transplant means a hospital stay, weeks of recovery, and months of close follow-up.

The comparison needs a fair reading. The groups were not chosen by lottery, so people able to have a transplant may have been healthier to begin with. And because the figures are about older people with advanced MDS, they shouldn’t be applied to someone with lower-risk MDS.

Timing shapes the choice too. Drug treatment is often used first to shrink disease before transplant, but waiting too long can let MDS advance and lower the chance of transplant success. People with lower-risk MDS may reasonably delay transplant while their counts stay stable.

The Main Risks Relapse Complications and GVHD

Non-relapse mortality means deaths from transplant complications rather than from the MDS itself. About 26% of people had died from complications by two years, rising to 34% by ten years.¹⁷ Most of these deaths come early, but the risk doesn’t vanish afterward. Among later deaths from 5 to 10 years, GVHD, infections, new cancers, and heart disease were the main causes.¹⁸ Long-term survivors can face lasting immune problems, organ damage from earlier treatment, and a higher chance of new cancers, which is why follow-up continues for years and why survivors need ongoing cancer screening and heart care.

This risk rises with age, from about 25% in the youngest groups to 36% in the oldest within five years.¹⁹ Older bodies tolerate the strain of pre-transplant treatment, infection, and GVHD less well, so complications are more likely to turn fatal. The rise is gradual, not a cutoff at one age, and fitness and other illnesses often matter as much as age itself.

Graft-versus-host disease (GVHD) happens when donor immune cells attack your body, often the skin, gut, liver, or eyes. The same donor cells also attack remaining MDS cells, lowering relapse risk.²⁰ In high-risk MDS, mild long-lasting GVHD was linked to longer survival.²¹ Severe GVHD, however, raised complication deaths enough to cancel that benefit.²²

Some signs of GVHD are worth reporting promptly: a new rash, especially on the palms, soles, or ears; persistent diarrhea or cramping in the first months; and yellowing of the skin or eyes, which may signal liver involvement. Later on, watch for dry eyes, dry mouth, or tight skin.

Infection is the other everyday danger. The immune system stays weak for months, often longer with GVHD treatment, so a fever is treated as an emergency in this period. Re-vaccination is usually needed, because the transplant wipes out much of the protection from earlier vaccines.

Age Health and Transplant Choices That Shift the Odds

Age matters but isn’t a cutoff. Two-year survival was about 41% at ages 65 to 69, 38% at 70 to 74, and 23% at 75 to 79.²³ Transplant can be a reasonable option into the mid-70s for fit people.²⁴ In one group, other health conditions affected survival more than transfusion history did.²⁵

A fitness evaluation includes heart, lung, and kidney tests to estimate complication risk, and a score of your ability to do daily activities. It also looks for infections, iron overload, and other illnesses that need treating first.

Frequent blood transfusions build up iron, which is measured by a blood test called ferritin that may appear on your results. Ferritin above 1000 µg/L before transplant was linked to lower survival.²⁶ High liver iron on MRI roughly doubled the risk of death from complications.²⁷ It is worth asking whether iron removal treatment makes sense before transplant.

Donor choice involves trade-offs. Younger unrelated donors led to fewer relapses than older matched siblings, 37% versus 50%.²⁸ Overall survival was similar, though, because sibling transplants caused less GVHD.²⁹

Cells collected from blood rather than bone marrow led to faster recovery and fewer early deaths in one group.³⁰ Transplanting soon after diagnosis was linked to longer survival than waiting beyond 6 months.³¹

Conditioning is the chemotherapy or radiation given before transplant to clear your marrow. Reduced-intensity and full-strength conditioning gave similar long-term survival in MDS.³² Gentler pre-transplant treatment caused fewer early deaths but allowed more relapse in some studies, which helps explain why the two come out even.³³

Practical factors count as well. Lower income was linked to higher death rates after transplant, likely from gaps in access and support. You’ll need a caregiver around the clock for the first weeks or months, and living near the transplant center, or arranging housing nearby, makes frequent visits easier.

Watching for Relapse and Preventing It

About 6 in 10 relapses happen within the first year, with half by about 6 months.³⁴ Testing is most frequent early on and spaced out as time passes without relapse.

When relapse does happen, timing predicts what follows. Relapse within 6 months or progression to leukemia predicted much shorter survival after relapse.³⁵ Median survival after relapse ranged from about 13 months in better-risk groups to 2.4 months in worse.³⁶

Follow-up usually means frequent blood counts in the first months, then less often. Bone marrow biopsies happen at set points, often 1, 3, 6, and 12 months. Donor chimerism tests, which may appear by that name on your results, check what share of your blood cells come from the donor. A high donor share is expected. A falling share can be an early sign that the transplant isn’t holding or that MDS cells are returning. It’s a warning signal rather than a diagnosis, so a change usually leads to further testing such as a marrow biopsy.

Measurable residual disease (MRD) means tiny amounts of MDS found by sensitive marrow tests. People without leftover disease after transplant had about a 6% relapse rate at three years, versus 83% with it.³⁷ Finding it early allows treatments like donor immune cell infusions or drugs before full relapse.³⁸

Maintenance treatment is another option. Low-dose azacitidine after transplant is well tolerated, with about 77% alive at two years in high-risk patients.³⁹ Venetoclax plus azacitidine maintenance may lower relapse rates.⁴⁰

Good questions for your team: whether you’re a candidate for maintenance therapy, how often leftover disease testing will be done, and what the plan is if early signs of relapse appear.

Preparing for Transplant With Bridging Treatment

About 4 in 10 people with high-risk MDS on venetoclax plus azacitidine went on to transplant.⁴¹ About 65% of those were alive at last check, and responders had better outcomes.⁴² In related leukemia, this combination caused fewer complication deaths than intensive chemotherapy before transplant.⁴³

The aim is to lower the blast count. Blasts are immature marrow cells that build up in MDS, and a high share at transplant means more disease for the new immune system to clear. A good response also tells the team the MDS is sensitive to treatment, which is part of why responders did better.

Bridging usually runs a few monthly cycles, about 5 to 6 months to transplant. Donor searching happens at the same time, and a marrow biopsy checks the response before transplant is scheduled.

It may be skipped. People with low blast counts may go straight to transplant, and delays risk losing a donor or letting the disease advance. The team balances shrinking the disease against waiting time.